These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 26101915)

  • 21. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back.
    Rossi V; Turati A; Rosato A; Carpanese D
    Front Immunol; 2024; 15():1447280. PubMed ID: 39211043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Gray JE; Heist RS; Starodub AN; Camidge DR; Kio EA; Masters GA; Purcell WT; Guarino MJ; Misleh J; Schneider CJ; Schneider BJ; Ocean A; Johnson T; Gandhi L; Kalinsky K; Scheff R; Messersmith WA; Govindan SV; Maliakal PP; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2017 Oct; 23(19):5711-5719. PubMed ID: 28679770
    [No Abstract]   [Full Text] [Related]  

  • 23. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 25. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130).
    Sharkey RM; Govindan SV; Cardillo TM; Donnell J; Xia J; Rossi EA; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2018 Jan; 17(1):196-203. PubMed ID: 29079710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.
    Weiten R; Niemann M; Below E; Friker LL; Ralser DJ; Toma M; Kristiansen G; Hahn O; Zechel S; Grünwald V; Bald T; Siewert J; Pietsch T; Ritter M; Hölzel M; Eckstein M; Alajati A; Krausewitz P; Klümper N
    Cancer Med; 2024 Jun; 13(12):e7320. PubMed ID: 38895886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
    Pandey R; Gruslova A; Chiou J; Brenner AJ; Tiziani S
    Anal Chem; 2020 Jan; 92(1):1260-1267. PubMed ID: 31765123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
    Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
    Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
    Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
    Zhu J; Wu W; Togashi Y; Taira Nihira N; Johmura Y; Zhu D; Nakanishi M; Miyoshi Y; Ohta T
    Breast Cancer; 2022 Nov; 29(6):1076-1087. PubMed ID: 35882754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
    Bardia A; Sun S; Thimmiah N; Coates JT; Wu B; Abelman RO; Spring L; Moy B; Ryan P; Melkonyan MN; Partridge A; Juric D; Peppercorn J; Parsons H; Wander SA; Attaya V; Lormil B; Shellock M; Nagayama A; Bossuyt V; Isakoff SJ; Tolaney SM; Ellisen LW
    Clin Cancer Res; 2024 Jul; 30(14):2917-2924. PubMed ID: 38709212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
    Liu D; Cardillo TM; Wang Y; Rossi EA; Goldenberg DM; Chang CH
    Mol Cancer; 2014 Mar; 13():53. PubMed ID: 24606732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
    Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
    Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
    Santi DV; Ashley GW; Cabel L; Bidard FC
    BioDrugs; 2024 Mar; 38(2):171-176. PubMed ID: 38236523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.
    Strop P; Tran TT; Dorywalska M; Delaria K; Dushin R; Wong OK; Ho WH; Zhou D; Wu A; Kraynov E; Aschenbrenner L; Han B; O'Donnell CJ; Pons J; Rajpal A; Shelton DL; Liu SH
    Mol Cancer Ther; 2016 Nov; 15(11):2698-2708. PubMed ID: 27582525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.